Protalix BioTherapeutics (PLX +2.3%) reverses morning losses to gain on news that Brazilian...


Protalix BioTherapeutics (PLX +2.3%) reverses morning losses to gain on news that Brazilian health authorities had given regulatory approval to Uplyso, a long-term enzyme replacement therapy for adults with Type I Gaucher disease. PLX has partnered with Pfizer (PFE +0.3%) to market and commercialise the drug worldwide, apart from Israel where it maintains exclusive rights.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs